{"id":77079,"date":"2026-08-28T21:12:46","date_gmt":"2026-08-28T13:12:46","guid":{"rendered":"https:\/\/flcube.com\/?p=77079"},"modified":"2026-08-28T21:12:47","modified_gmt":"2026-08-28T13:12:47","slug":"duality-biologics-and-genentech-strike-global-adc-collaboration-with-usd-1b-milestone-potential","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=77079","title":{"rendered":"Duality Biologics and Genentech Strike Global ADC Collaboration with USD 1b+ Milestone Potential"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Duality Biologics<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/beta\/quote\/9606:HKG\">HKG: 9606<\/a>) announced that it has entered into a global collaboration and license agreement with <strong>Genentech<\/strong>, a member of the <strong>Roche Group<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/beta\/quote\/ROP:SWX\">SWX: ROP<\/a>; <a href=\"https:\/\/www.google.com\/finance\/beta\/quote\/RHHBY:OTCMKTS\">OTCMKTS: RHHBY<\/a>), to develop next-generation <strong>antibody-drug conjugates (ADCs)<\/strong> based on <strong>Duality Biologics&#8217;<\/strong> proprietary DualityBio Unique Payload Antibody Conjugate Platform (<strong>DUPAC<\/strong>). The deal, featuring a USD 45m upfront payment and over USD 1b in potential milestones, marks another major validation of Chinese ADC platform technology by a top-tier global pharma player.<\/p>\n\n\n\n<h2 id=\"h-deal-overview\" class=\"wp-block-heading\">Deal Overview<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Element<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td>Parties<\/td><td><strong>Duality Biologics<\/strong> (HKG: 9606) and <strong>Genentech<\/strong> (Roche Group)<\/td><\/tr><tr><td>Agreement Type<\/td><td>Global collaboration and license agreement<\/td><\/tr><tr><td>Scope<\/td><td>Next-generation <strong>ADCs<\/strong> based on the <strong>DUPAC<\/strong> platform against tumor targets designated by Genentech<\/td><\/tr><tr><td>Upfront Payment<\/td><td>USD 45m<\/td><\/tr><tr><td>Potential Milestones<\/td><td>Over USD 1b across development, regulatory, and commercial milestones (all programs)<\/td><\/tr><tr><td>Royalties<\/td><td>Tiered royalties based on annual net sales of approved products<\/td><\/tr><tr><td>Date<\/td><td>28 Aug 2026<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-platform-amp-responsibilities\" class=\"wp-block-heading\">Platform &amp; Responsibilities<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Technology:<\/strong> The <strong>DUPAC<\/strong> (DualityBio Unique Payload Antibody Conjugate) platform, <strong>Duality Biologics&#8217;<\/strong> proprietary novel payload antibody conjugate platform<\/li>\n\n\n\n<li><strong>Duality Biologics&#8217; Role:<\/strong> Utilize DUPAC payloads to generate and develop ADCs against Genentech-designated tumor targets; lead drug discovery and global early-stage clinical development<\/li>\n\n\n\n<li><strong>Genentech&#8217;s Role:<\/strong> Obtain exclusive global licenses to the collaboration ADCs; independently assume responsibility for subsequent clinical development and commercialization following completion of Phase Ia<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-division-of-labor-by-development-stage\" class=\"wp-block-heading\">Division of Labor by Development Stage<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Stage<\/th><th>Lead Party<\/th><\/tr><\/thead><tbody><tr><td>Drug discovery &amp; ADC generation<\/td><td><strong>Duality Biologics<\/strong><\/td><\/tr><tr><td>Global early-stage clinical development (through Phase Ia)<\/td><td><strong>Duality Biologics<\/strong><\/td><\/tr><tr><td>Late-stage clinical development (post-Phase Ia)<\/td><td><strong>Genentech<\/strong><\/td><\/tr><tr><td>Commercialization<\/td><td><strong>Genentech<\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">Under the structure, <strong>Duality Biologics<\/strong> retains control through the earliest clinical proof point, after which <strong>Genentech<\/strong> \u2014 one of the world&#8217;s leading oncology companies \u2014 takes over full development and commercialization. This handoff model lets the biotech focus capital on discovery and early clinical execution while leveraging <strong>Genentech&#8217;s<\/strong> global late-stage machinery.<\/p>\n\n\n\n<h2 id=\"h-market-impact-amp-outlook\" class=\"wp-block-heading\">Market Impact &amp; Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Platform Validation:<\/strong> A collaboration with <strong>Genentech<\/strong> built on the <strong>DUPAC<\/strong> platform \u2014 not a single asset \u2014 signals confidence in <strong>Duality Biologics&#8217;<\/strong> next-generation payload technology as a durable engine for <strong>ADC<\/strong> innovation<\/li>\n\n\n\n<li><strong>Economics:<\/strong> The USD 45m upfront, USD 1b+ milestone stack, and tiered royalties provide a multi-year, diversified revenue profile without diluting equity<\/li>\n\n\n\n<li><strong>ADC Sector Momentum:<\/strong> The deal extends the wave of global pharma licensing China-originated ADC science, reinforcing the country&#8217;s position as a hotbed of conjugate technology<\/li>\n\n\n\n<li><strong>Strategic Optionality:<\/strong> With <strong>Genentech<\/strong> financing late-stage development and commercialization, <strong>Duality Biologics<\/strong> (HKG: 9606) preserves resources to expand its own pipeline and pursue additional platform partnerships<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong> \u2013 This brief contains forward-looking statements regarding collaboration outcomes, milestone achievement, and product commercialization. Milestone payments are contingent on future events and may not be realized. Not investment advice.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Duality Biologics (HKG: 9606) announced that it has entered into a global collaboration and license&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,10],"tags":[35,232,1111,3974,940,939],"class_list":["post-77079","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-adc-xdc","tag-duality-biologics","tag-genentech","tag-hkg-9606","tag-otcmkts-rhhby","tag-swx-rop"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v28.3) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Duality Biologics and Genentech Strike Global ADC Collaboration with USD 1b+ Milestone Potential - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Duality Biologics (HKG: 9606) announced that it has entered into a global collaboration and license agreement with Genentech, a member of the Roche Group (SWX: ROP; OTCMKTS: RHHBY), to develop next-generation antibody-drug conjugates (ADCs) based on Duality Biologics&#039; proprietary DualityBio Unique Payload Antibody Conjugate Platform (DUPAC). The deal, featuring a USD 45m upfront payment and over USD 1b in potential milestones, marks another major validation of Chinese ADC platform technology by a top-tier global pharma player.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=77079\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Duality Biologics and Genentech Strike Global ADC Collaboration with USD 1b+ Milestone Potential\" \/>\n<meta property=\"og:description\" content=\"Duality Biologics (HKG: 9606) announced that it has entered into a global collaboration and license agreement with Genentech, a member of the Roche Group (SWX: ROP; OTCMKTS: RHHBY), to develop next-generation antibody-drug conjugates (ADCs) based on Duality Biologics&#039; proprietary DualityBio Unique Payload Antibody Conjugate Platform (DUPAC). The deal, featuring a USD 45m upfront payment and over USD 1b in potential milestones, marks another major validation of Chinese ADC platform technology by a top-tier global pharma player.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=77079\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-08-28T13:12:46+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-08-28T13:12:47+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=77079#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=77079\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Duality Biologics and Genentech Strike Global ADC Collaboration with USD 1b+ Milestone Potential\",\"datePublished\":\"2026-08-28T13:12:46+00:00\",\"dateModified\":\"2026-08-28T13:12:47+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=77079\"},\"wordCount\":443,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"ADC \\\/ XDC\",\"Duality Biologics\",\"Genentech\",\"HKG: 9606\",\"OTCMKTS: RHHBY\",\"SWX: ROP\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=77079#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=77079\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=77079\",\"name\":\"Duality Biologics and Genentech Strike Global ADC Collaboration with USD 1b+ Milestone Potential - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-08-28T13:12:46+00:00\",\"dateModified\":\"2026-08-28T13:12:47+00:00\",\"description\":\"Duality Biologics (HKG: 9606) announced that it has entered into a global collaboration and license agreement with Genentech, a member of the Roche Group (SWX: ROP; OTCMKTS: RHHBY), to develop next-generation antibody-drug conjugates (ADCs) based on Duality Biologics' proprietary DualityBio Unique Payload Antibody Conjugate Platform (DUPAC). The deal, featuring a USD 45m upfront payment and over USD 1b in potential milestones, marks another major validation of Chinese ADC platform technology by a top-tier global pharma player.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=77079#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=77079\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=77079#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Duality Biologics and Genentech Strike Global ADC Collaboration with USD 1b+ Milestone Potential\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Duality Biologics and Genentech Strike Global ADC Collaboration with USD 1b+ Milestone Potential - Insight, China&#039;s Pharmaceutical Industry","description":"Duality Biologics (HKG: 9606) announced that it has entered into a global collaboration and license agreement with Genentech, a member of the Roche Group (SWX: ROP; OTCMKTS: RHHBY), to develop next-generation antibody-drug conjugates (ADCs) based on Duality Biologics' proprietary DualityBio Unique Payload Antibody Conjugate Platform (DUPAC). The deal, featuring a USD 45m upfront payment and over USD 1b in potential milestones, marks another major validation of Chinese ADC platform technology by a top-tier global pharma player.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=77079","og_locale":"en_US","og_type":"article","og_title":"Duality Biologics and Genentech Strike Global ADC Collaboration with USD 1b+ Milestone Potential","og_description":"Duality Biologics (HKG: 9606) announced that it has entered into a global collaboration and license agreement with Genentech, a member of the Roche Group (SWX: ROP; OTCMKTS: RHHBY), to develop next-generation antibody-drug conjugates (ADCs) based on Duality Biologics' proprietary DualityBio Unique Payload Antibody Conjugate Platform (DUPAC). The deal, featuring a USD 45m upfront payment and over USD 1b in potential milestones, marks another major validation of Chinese ADC platform technology by a top-tier global pharma player.","og_url":"https:\/\/flcube.com\/?p=77079","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-08-28T13:12:46+00:00","article_modified_time":"2026-08-28T13:12:47+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=77079#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=77079"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Duality Biologics and Genentech Strike Global ADC Collaboration with USD 1b+ Milestone Potential","datePublished":"2026-08-28T13:12:46+00:00","dateModified":"2026-08-28T13:12:47+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=77079"},"wordCount":443,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["ADC \/ XDC","Duality Biologics","Genentech","HKG: 9606","OTCMKTS: RHHBY","SWX: ROP"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=77079#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=77079","url":"https:\/\/flcube.com\/?p=77079","name":"Duality Biologics and Genentech Strike Global ADC Collaboration with USD 1b+ Milestone Potential - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-08-28T13:12:46+00:00","dateModified":"2026-08-28T13:12:47+00:00","description":"Duality Biologics (HKG: 9606) announced that it has entered into a global collaboration and license agreement with Genentech, a member of the Roche Group (SWX: ROP; OTCMKTS: RHHBY), to develop next-generation antibody-drug conjugates (ADCs) based on Duality Biologics' proprietary DualityBio Unique Payload Antibody Conjugate Platform (DUPAC). The deal, featuring a USD 45m upfront payment and over USD 1b in potential milestones, marks another major validation of Chinese ADC platform technology by a top-tier global pharma player.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=77079#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=77079"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=77079#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Duality Biologics and Genentech Strike Global ADC Collaboration with USD 1b+ Milestone Potential"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"","_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/77079","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=77079"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/77079\/revisions"}],"predecessor-version":[{"id":77080,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/77079\/revisions\/77080"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=77079"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=77079"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=77079"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}